RemeGen Co., Ltd. (HKG:9995)
Hong Kong · Delayed Price · Currency is HKD 79.35
-1.35 (-1.67%)
Sep 1, 2026, 4:08 PM HKT
RemeGen Market Cap
RemeGen has a market cap or net worth of 65.83 billion as of September 1, 2026. Its market cap has increased by 19.72% in one year.
Market Cap
65.83B
Enterprise Value
60.25B
Revenue
9.24B
Ranking
n/a
PE Ratio
6.62
Stock Price
79.35
ChartMarket Cap Chart
Since November 9, 2020, RemeGen's market cap has increased from 33.39B to 65.83B, an increase of 97.14%. That is a compound annual growth rate of 12.38%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 1, 2026 | 65.86B | 45.70% |
| Dec 31, 2025 | 45.20B | 222.75% |
| Dec 31, 2024 | 14.00B | -55.02% |
| Dec 29, 2023 | 31.13B | -25.43% |
| Dec 30, 2022 | 41.75B | 9.42% |
| Dec 31, 2021 | 38.16B | -18.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Nov 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Innovent Biologics | 176.88B |
| Sichuan Kelun-Biotech Biopharmaceutical | 117.07B |
| Sino Biopharmaceutical | 93.68B |
| Akeso | 82.81B |
| Genscript Biotech | 79.51B |
| Biocytogen Pharmaceuticals (Beijing) | 53.92B |
| 3SBio | 40.02B |
| Shanghai Henlius Biotech | 35.87B |